Hyper-activation of PI-3K/AKT signaling as well as its downstream target mTORC1 has been frequently observed in a subset of ccRCC patients [22], leading to the commencement of a clinical trial investigating everolimus therapy on ccRCC [23]. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.